Meftal%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520spas

# Meftal spas ## Overview Meftal spas is a combination product containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and hyoscine butylbromide, an antispasmodic agent. ## Primary Indications * Symptomatic relief of pain and spasms associated with irritable bowel syndrome (IBS). * Management of abdominal pain and cramps. ## Adult Dosing * **Standard dose:** 1 tablet (mefenamic acid 250 mg / hyoscine butylbromide 10 mg) three times daily. * **Maximum dose:** Not explicitly defined for the combination product. Mefenamic acid typically has a maximum daily dose of 1500 mg. Hyoscine butylbromide typically has a maximum daily dose of 100 mg. Adhere to individual component maximums and clinical judgment. ## Pediatric Dosing * Dosing for Meftal spas in pediatric patients is not well-established. Mefenamic acid dosing in children over 6 months is generally 5-7 mg/kg/dose every 6-8 hours. Hyoscine butylbromide is generally not recommended for pediatric use unless specifically indicated and dosed by a specialist. **Consultation with a pediatrician or specialist is strongly recommended.** ## Dose Adjustments * **Renal Impairment:** Mefenamic acid should be used with caution in patients with renal impairment. Dose reduction may be necessary. * **Hepatic Impairment:** Mefenamic acid should be used with caution in patients with hepatic impairment. Dose reduction may be necessary. * **Elderly:** Use with caution. Mefenamic acid is associated with increased risk of gastrointestinal bleeding, renal, hepatic, and cardiac events. ## Contraindications * Hypersensitivity to mefenamic acid, hyoscine butylbromide, or any excipient. * Active peptic ulceration or history of recurrent peptic ulceration. * Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis). * Severe renal, hepatic, or cardiac failure. * Known bronchospasm or other allergic-type reactions after taking aspirin or other NSAIDs. * Obstructive gastrointestinal or urinary tract conditions. * Tachyarrhythmias. * Myasthenia gravis. * Glaucoma (specifically narrow-angle glaucoma is a concern with anticholinergics like hyoscine). ## Adverse Effects * **Common (Mefenamic Acid):** Nausea, vomiting, diarrhea, abdominal pain, dyspepsia, constipation, headache, dizziness. * **Serious (Mefenamic Acid):** Gastrointestinal bleeding, perforation, ulceration, renal failure, hepatic dysfunction, cardiovascular thrombotic events, hypersensitivity reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis. * **Common (Hyoscine Butylbromide):** Dry mouth, blurred vision, urinary retention, constipation, tachycardia, drowsiness. * **Serious (Hyoscine Butylbromide):** Angle-closure glaucoma, severe allergic reactions. ## Key Drug Interactions * **Mefenamic Acid:** * **Anticoagulants (e.g., warfarin):** Increased risk of bleeding. * **Corticosteroids:** Increased risk of GI ulceration and bleeding. * **SSRIs:** Increased risk of GI bleeding. * **Diuretics, ACE inhibitors, ARBs:** Reduced antihypertensive effect, increased risk of renal impairment. * **Lithium:** Increased lithium levels. * **Methotrexate:** Increased methotrexate toxicity. * **Hyoscine Butylbromide:** * **Other Anticholinergics:** Additive anticholinergic effects. * **Dopamine antagonists (e.g., metoclopramide):** May reduce the efficacy of both drugs. * **Tricyclic antidepressants, MAOIs:** May potentiate anticholinergic effects. ## Monitoring * **Gastrointestinal:** Monitor for signs and symptoms of bleeding (e.g., melena, hematemesis). * **Renal Function:** Baseline and periodic monitoring of serum creatinine and BUN, especially in patients with pre-existing renal disease or those on concomitant nephrotoxic agents. * **Hepatic Function:** Baseline and periodic monitoring of liver enzymes, especially in patients with pre-existing liver disease. * **Blood Pressure:** Monitor blood pressure, especially with long-term NSAID use. * **Signs of hypersensitivity:** Monitor for rash, pruritus, and other signs of allergic reaction. ## Clinical Pearls * Meftal spas should be used for the shortest duration necessary to control symptoms. * Concurrent use of gastroprotective agents (e.g., proton pump inhibitors) may be considered, especially in patients with a history of GI events or those at higher risk. * Caution in patients with a history of asthma, as NSAIDs can exacerbate it. * Discontinue immediately if signs of serious adverse reactions (e.g., GI bleeding, severe skin reactions, cardiovascular events) occur. * The antispasmodic component (hyoscine butylbromide) may cause drowsiness; patients should exercise caution when driving or operating machinery. --- **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and local guidelines before making any treatment decisions.